Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
Publishing timestamp: 2024-01-02 16:49:09
Summary
Moderna's stock jumped after Oppenheimer upgraded it, stating that the company could market five products by 2026. The upgrade follows a challenging year for Moderna, whose only commercially available product is its Covid vaccine. The analyst is optimistic about Moderna's pipeline potential, highlighting potential product launches in the next 12 to 18 months that could boost sales in 2025. The article also mentions Moderna's experimental vaccines for respiratory syncytial virus and the flu, as well as its experimental personalized cancer vaccine. Moderna expects sales growth in 2025 and plans to launch up to 15 products in the next five years.
Sentiment: POSITIVE
Keywords: breaking news, biotechnology, business news, merck & co inc, health care industry, pharmaceuticals, business, moderna inc, science, biotech and pharmaceuticals,